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Background: Metabolic syndrome (MeS) is being recognized as a risk factor for insulin resistance and
cardiovascular disease. The present study was aimed to find out the possible association between 45-bp I/D
polymorphism of uncoupling protein 2 (UCP2) and MeS.
Methods: DNA was extracted from peripheral blood of 151 subjects with and 149 subjects without MeS. 45-bp I/D
variant of UCP2 was detected using polymerase chain reaction (PCR).
Results: Our finding showed that 45-bp I/D polymorphism was associated with protection against MeS (OR = 0.56,
95% CI = 0.34-0.92, p = 0.020 D/I vs DD and OR = 0.54, 95% CI = 0.34-0.86, p = 0.009; D/I + I/I vs D/D). The I allele
decreased the risk of MeS (OR = 0.62, 95% CI = 0.44-0.90, p = 0.011) in comparison with D allele.
Conclusion: In conclusion, our result suggests that 45-bp I/D polymorphism is associated with the risk of MeS,
which remains to be cleared.
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Metabolic syndrome (MeS) is described as the combin-
ation of clinical disorders that increase the risk for obesity
(central adiposity), insulin resistance, glucose intolerance,
dyslipidemia, non-alcoholic fatty liver disease and cardio-
vascular diseases including atherosclerosis, stroke and
hypertension [1,2]. The prevalence of MeS is considerably
increasing globally, and is becoming an important health
problem [3]. The etiology of this syndrome is complex
and is thought to be the result of interaction between gen-
etic and environmental factors [4-6]. Uncoupling proteins
(UCPs) are mitochondrial membrane transporters that
disturb the coupling between the mitochondrial proton
gradient and ATP synthesis. In humans, the gene for
UCP2 is located on chromosome 11q13 and contains 8
exons which exons 1 and 2 of UCP2 are untranslated [7].
Among the five UCP homologs (UCP1–UCP5), UCP2 is
the most widely expressed, being involved in thermal* Correspondence: mhd.hashemi@gmail.com
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reproduction in any medium, provided the orregulation in various tissues, including white adipose tis-
sue, liver, kidney, pancreatic islets, macrophages as well as
retinal endothelial cells [8,9], and it is thought to play a
role in the progress of obesity [10]. This protein uncouples
oxidation of substrate from phosphorylation, dissipating
the membrane potential energy and consequently decreas-
ing ATP production by the mitochondrial respiratory
chain [8]. It has been proposed that uncoupling leads to
tissue-specific functions such as decreasing ROS forma-
tion by mitochondria, regulation of free fatty acids metab-
olism and inhibition of insulin secretion from beta cells
[8,11]. Increased ROS production has been observed in
macrophages [12] and pancreatic islets of UCP2 knockout
mice [13]. It has been reported that overexpression of
UCP2 attenuates ROS production and prevents oxidative
damage of tissues [14,15]. α-Cells of pancreas secrete glu-
cagon in response to low blood glucose. It has been shown
that UCP2 is required for appropriate glucagon secretion
and the absence of UCP2 impairs α-cell function [16].
The dysregulation of uncoupling proteins (UCPs), which
translocate protons into the mitochondrial matrix result-
ing in heat generation without ATP synthesis [17], may
contribute to the pathogenesis of obesity. It has been pro-
posed that carriers of the exon-8 insertion allele in theal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Map of the human UCP2 gene. Exons 1–8 are numbered and represented by black (coding exons) and white boxes (3′ and 5′ UTRs). Position
of the 45-bp insertion/deletion in exon 8 in the 3′ UTR is designated.
Figure 2 Representative PCR products resolved by agarose gel
electrophoresis to detect the presence or absence of the 45 bp I/D
of UCP2 gene.M, DNA marker. Lanes 1, 6: I/I; lane 2: D/D; lanes 3,4,5: I/D.
Hashemi et al. Journal of Diabetes & Metabolic Disorders 2014, 13:12 Page 2 of 5
http://www.jdmdonline.com/content/13/1/12UCP2 gene may have a greater risk of developing obesity
[18]. Papazoglou et al. have found no association between
UCP2 ins/del polymorphism and morbid obesity [19]. No
association between UCP2-45 bp I/D and obesity was
found in a Chinese population [20]. It has been shown that
the UCP gene cluster variation may not be useful predictor
for type 2 diabetes mellitus (T2DM) risk assessment [21].
In the current study, we aimed to evaluate the possible
association between UCP 45-bp I/D and MeS in a sample
of Iranian population.
Materials and methods
This case-control study was done on 151 patients with
and 149 without MeS which we used in previous studies
[4,5]. MeS was defined using the National Cholesterol
Education Program Adult Treatment Panel III (NCEP
ATP III) criteria [22] as described previously [23]. Ethical
approvals for recruitment were obtained from local Ethics
Committee of Zahedan University of Medical Sciences,
and informed consent was obtained from all individuals.
The data included weight, height, waist circumference,
systolic and diastolic blood pressure; blood levels of
glucose, triglycerides, total cholesterol, HDL cholesterol
and LDL cholesterol were collected as described previously
[23-25]. Blood samples were collected in EDTA-containing
tubes and genomic DNA were extracted using salting out
method as described previously [26].
Position of the 45-bp I/D polymorphism of UCP2 is
shown schematically in Figure 1. The forward and reverse
primers for detection of 45-bp ins/del polymorphism were
5′-TCTGGCTGAACTTTCCAA-3′ and 5′-TTCATGCC
CTCCTTTCTC-3′, respectively. PCR was performed by
using commercially available PCR premix (AccuPower
PCR PreMix; BIONEER, Daejeon, Korea) according to the
manufacturer’s instructions. Briefly, 1 μL template DNA
(~100 ng/mL), 1 μL of each primer (10 pmol/mL), and
17 μL DNase-free water were added to AccuPower PCR
PreMix. Amplification was done with an initial denatur-
ation step at 95°C for 5 min, followed by 30 cycles at 95°C
for 30 s, 60°C for 30 s, and 72°C for 23 s with a final exten-
sion at 72°C for 10 min. The amplified PCR product was
resolved on 2% agarose gel. The PCR products for insertion
and deletion alleles were 428-bp and 383-bp, respectively(Figure 2). Random samples were regenotyped to verify the
accuracy of genotyping. We found no genotyping mistake.
Statistical Analysis
The differences between the categorical and contentious
data were assessed by chi-square and independent sample
t-tests, respectively. The association between genotypes
and metabolic syndrome was assessed by computing the
odds ratio (OR) and 95% confidence intervals (95% CI)
from logistic regression analyses. P-value less than 0.05
were considered statistically significant. The data analysis
was performed using the SPSS18 software. According to
our findings, sample power was calculated by using STATA
10 software.
Results
A total of 300 subjects including 151 MeS patients and
149 subjects without MeS were recruited in the study. The
demographic and biochemical characteristics of the study
participants are shown in Table 1. There were no signifi-
cant differences between the groups regarding sex and age
(p > 0.05). As shown in Table 2, our finding showed that
the 45-bp I/D polymorphism of UCP2 decreased the risk of
MeS in codominant (OR = 0.56, 95%CI = 0.34-0.92,
p = 0.020 D/I vs D/D) and dominant (OR = 0.54, 95%
CI = 0.34-0.86, p = 0.009; D/I + I/I vs D/D) inheritance
model tested (Table 2). The I allele is associated with
Table 1 Demoraphic, clinical and biochemical




Sex (M/F) 45/104 50/101 0.901
Age (year) 43.53 ± 11.96 41.98 ± 14.65 0.382
Height (cm) 160.21 ± 9.54 161.33 ± 10.24 0.330
Weight (kg) 71.07 ± 16.48 66.35 ± 14.19 0.009
BMI (kg/m2) 27.59 ± 5.40 25.49 ± 4.89 0.001
Waist circumference (cm) 95.36 ± 15.54 90.19 ± 12.87 0.002
FBG (mg/dL) 96.51 ± 25.99 94.25 ± 31.27 0.459
Triglycerides (mg/dL) 184.03 ± 110.81 141.66 ± 67.23 <0.001
Total cholestrol (mg/dL) 200.03 ± 45.74 190.91 ± 39.09 0.065
HDL-C (mg/dL) 43.05 ± 9.06 45.61 ± 7.70 0.019
LDL-C (mg/dL) 120.21 ± 44.76 116.78 ± 34.61 0.460
SBP (mmHg) 122.85 ± 17.90 117.49 ± 21.57 0.020
DBP (mmHg) 77.32 ± 13.51 73.95 ± 13.61 0.032
FBG, fasting blood glucose; SBP, systolic blood pressure; DBP, diastolic
blood pressure.
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p = 0.011) in comparison to D allele.
The genotype distribution of 45-bp I/D polymorphism
of UCP2 in subjects with and without MeS were in Hardy
Weinberg equilibrium (HWE) (χ2 = 1.173, p = 0.278,
χ2 = 0.042, p = 0.837, respectively).
Discussion
In the present study, we analyzed the possible association
45-bp I/D polymorphism of UCP2 gene and MeS in a
sample of Iranian population. The UCP2 45-bp I/D wasTable 2 Association of the 45-bp I/D polymorphism of UCP2 g
syndrome (MeS)
UCP2 (45-bp I/D) MeS (yes) MeS (No)
Codominant
D/D 90 (59.6) 67 (45.0)
D/I 50 (33.1) 65 (43.6)
I/I 11 (7.3) 17 (11.4)
Dominanat
D/D 90 (59.6) 67 (45.0)
D/I + I/I 61 (40.4) 82 (55.0)
Recessive
D/D + D/I 140 (92.7) 132 (88.6)
I/I 11 (7.3) 17 (11.4)
Alleles
D 230 (76.2) 199 (66.8)
I 72 (23.8) 99 (33.2)
aAdjusted for sex and age.associated with MeS, so that the frequency distribution of
I/D genotype as well as I allele were significantly lower
in cases than that of controls. Metabolic syndrome is a
combination of risk factors for cardiovascular disease
(CVD) and T2DM. These factors include hyperglycemia,
hypertension, dyslipidemia (high level of triglyceride and
low HDL-cholesterol), and obesity (particularly with
abdominal localization) [23,27]. Prevalence of MeS
varies globally and depends in part on lifestyle, sex, age
and ethnicity [23,28].
Some studies have found no associations between UCP2
45-bp I/D polymorphism and obesity, resting energy
expenditure, BMI and insulin secretion [29-32]. Though,
in some studies, the I-allele of UCP-2 has been found to
be associated with development of obesity [18,33-35].
Oguzkan-Balci et al. [36] have found That UCP I/I geno-
type as well as I allele was associated with childhood
obesity and related metabolic disorders.
Papazoglou et al. [19] have found no association
between UCP2 45-bp I/D polymorphism and morbid
obesity. They found that this polymorphism has effect on
weight loss in metabolically healthy subjects so that indi-
viduals with I-allele had significantly greater reduction
in body mass index (BMI) and fat-free mass as well as a
slight significant improvement in the homeostatic
model assessment index. No association was found
between UCP2 45-bp I/D and obesity in a Chinese
population [20] as well as Italian Caucasians [37].
Crispim et al. [38] investigated the -866G/A (rs659366),
Ala55Val (rs660339) and 45 bp I/D polymorphisms in the
UCP2 gene in diabetes mellitus. They found that the
haplotype [A Val I] appears to be an important risk factor
associated with proliferative diabetic retinopathy in both
type 1 and 2 diabetic groups.ene in individulas with and without metabolic
aOR (95% CI) p Study power %
1.00 - 68
0.56 (0.34-0.92) 0.020 42




0.60 (0.27-1.34) 0.213 18
1.00 - 70
0.62 (0.44-0.90) 0.011 70
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decreased the risk of end-stage renal disease (ESRD) [39].
Mitchell et al. [40] have found no association between
UCP2 I/D polymorphism and neural tube defects (NTDs).
While, Wang et al. [41] proposed that this variant might
be a potential genetic risk factor for NTDs.
It has been proposed that impaired adipose tissue
expression of UCP2 may play a role in the pathophysiology
of obesity [42]. To date, very little is known about the
biological effects of the UCP2 45-bp I/D polymorphism,
although its location in the 3′UTR of exon 8 suggests its
potential involvement in mRNA processing or in transcript
stability. It has been reported that UCP2 45-bp I/D poly-
morphism had no apparent effect on skeletal muscle UCP2
mRNA levels in 22 randomly chosen Pima Indians [43].
Wang et al. have reported that 3′UTR I/D variant had
no impact on adipose mRNA levels [44]. Esterbauer
et al. showed that the ratio of inserted to deleted mRNA
expression was highly variable in the adipose tissue of
subjects heterozygous for 45-bp I/D. The findings sug-
gested an independent role for the 3′UTR I/D variant
in mRNA stability [45].
One of the limitations of the present study is relatively
small sample size. Consequently, analysis according to
MeS components was not possible.
In conclusion, our findings showed that the 45-bp I/D
polymorphism of UCP2 was associated with decreased
risk of MeS. Larger studies with different ethnicity are
required to validate our findings.
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